EUR-1008 (APT-1008)
Sponsors
Forest Laboratories
Conditions
Cystic FibrosisExocrine Pancreatic Insufficiency
Phase 3
Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
CompletedNCT00297167
Start: 2006-05-31End: 2006-11-30Updated: 2017-03-16
Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
CompletedNCT00981214
Start: 2006-05-31End: 2006-09-30Updated: 2017-03-16
Phase 4
A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age
CompletedNCT01100606
Start: 2010-06-30End: 2010-12-31Updated: 2014-04-10
PR-018: An Open-Label, Safety Extension of Study PR-011
CompletedNCT01131507
Start: 2010-07-31End: 2011-12-31Updated: 2017-03-21